Download PDF
Semin Respir Crit Care Med 2008; 29(1): 075-082
DOI: 10.1055/s-2008-1047565
© Thieme Medical Publishers

Venous Thromboembolism Prophylaxis for the Medical Patient: Where Do We Stand?

Yshai Yavin1 , Alexander T. Cohen1
  • 1Vascular Medicine, Department of Vascular Surgery, King's College Hospital, London, United Kingdom
Further Information

Publication History

Publication Date:
26 March 2008 (online)

    Permissions and Reprints

ABSTRACT

Acutely ill medical patients are at moderate to high risk of venous thromboembolism: ~10 to 30% of general medical patients may develop deep vein thrombosis or pulmonary embolism, and the latter is a leading contributor to deaths in hospital. Medical conditions associated with a high risk of venous thromboembolism include cardiac disease, cancer, respiratory disease, inflammatory bowel disease, and infectious diseases. Predisposing risk factors in medical patients include a history of venous thromboembolism, history of malignancy, complicating infections, increasing age, thrombophilia, prolonged immobility, and obesity. Heparins, including unfractionated and low molecular weight, as well as fondaparinux have been shown to be effective agents in prevention of VTE in this setting. However, it has not yet been possible to demonstrate a significant effect on mortality rates in this population. In medical patients, unfractionated heparin has a higher rate of bleeding complications than low molecular weight heparin. There is no evidence for the use of aspirin, warfarin, or mechanical methods. We recommend either low molecular weight heparin or fondaparinux as safe and effective agents in the thromboprophylaxis of medical patients.

KEYWORDS

Medical illness - risk assessment model - thromboprophylaxis - venous thromboembolism

REFERENCES

  • 1 Lindblad B, Sternby N H, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years.  BMJ. 1991;  302 709-711
    PubMedGoogle Scholar
  • 2 Sandler D A, Martin J F. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?.  J R Soc Med. 1989;  82 203-205
    CrossrefPubMedGoogle Scholar
  • 3 Cohen A T, Edmondson R A, Phillips M J, Ward V P, Kakkar V V. The changing pattern of venous thromboembolic disease.  Haemostasis. 1996;  26 65-71
    PubMedGoogle Scholar
  • 4 Geerts W H, Pineo G F, Heit J A et al.. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126 338S-400S
    CrossrefPubMedGoogle Scholar
  • 5 Sperry K L, Key C R, Anderson R E. Toward a population-based assessment of death due to pulmonary embolism in New Mexico.  Hum Pathol. 1990;  21 159-165
    CrossrefPubMedGoogle Scholar
  • 6 Shojania K G, Duncan B W, McDonald K M et al.. Making health care safer: a critical analysis of patient safety practices. Evidence Report/Technology Assessment No. 43 (Prepared by the University of California at San Francisco Stanford Evidence-Based Practice Center under Contract No. 290-97-0013). Rockville, MD; Agency for Healthcare Research and Quality July 2001: 332-346 AHRQ Publication No. 01-E058 http://Available at www.ahrq.gov/clinic/pt-safety/ Accessed January 3, 2002
    Google Scholar
  • 7 Samama M M, Cohen A T, Darmon J-Y et al.. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients.  N Engl J Med. 1999;  341 793-800
    CrossrefPubMedGoogle Scholar
  • 8 Leizorovicz A, Cohen A T, Turpie A GG, Olsson C G, Vaitkus P T, Goldhaber S Z. A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.  Circulation. 2004;  110 874-879
    CrossrefPubMedGoogle Scholar
  • 9 Nicolaides A N, Breddin H K, Fareed J et al.. Prevention of venous thromboembolism. International Consensus Statement Guidelines compiled in accordance with the scientific evidence.  Int Angiol. 2001;  20 1-37
    PubMedGoogle Scholar
  • 10 Anderson F A, Wheeler H B, Goldberg R J, Hosmer D W, Forcier A, Patwardhan N A. Physician practices in the prevention of venous thromboembolism.  Ann Intern Med. 1991;  115 591-595
    CrossrefPubMedGoogle Scholar
  • 11 Ageno W, Squizzata A, Ambrosini F et al.. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns.  Haematologica. 2002;  87 746-750
    PubMedGoogle Scholar
  • 12 Ahmad H A, Geissler A, Maclellan D G. Deep venous thrombosis prophylaxis: are guidelines being followed?.  ANZ J Surg. 2002;  72 331-334
    CrossrefPubMedGoogle Scholar
  • 13 Bergmann J-F, Mouly S. Thromboprophylaxis in medical patients: focus on France.  Semin Thromb Hemost. 2002;  28(Suppl 3) 51-55
    PubMedGoogle Scholar
  • 14 Arcelus J I, Candocia S, Traverso C I, Fabrega F, Caprini J A, Hasty J H. Venous thromboembolism prophylaxis and risk assessment in medical patients.  Semin Thromb Hemost. 1991;  17(Suppl 3) 313-318
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Geerts W H, Heit J A, Clagett G P et al.. Prevention of venous thromboembolism.  Chest. 2001;  119 132S-175S
    CrossrefPubMedGoogle Scholar
  • 16 Emerson P A, Marks P. Preventing thromboembolism after myocardial infarction: effect of low-dose heparin or smoking.  BMJ. 1977;  1 18-20
    PubMedGoogle Scholar
  • 17 Handley A J. Low-dose heparin after myocardial infarction.  Lancet. 1972;  2 623-624
    PubMedGoogle Scholar
  • 18 Warlow C, Beattie A G, Terry G, Ogston D, Kenmure A CF, Douglas A S. A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction.  Lancet. 1973;  2 934-936
    PubMedGoogle Scholar
  • 19 Belch J J, Lowe G DO, Ward A G, Forbes C D, Prentice C RM. Prevention of deep vein thrombosis in medical patients by low-dose heparin.  Scott Med J. 1981;  26 115-117
    PubMedGoogle Scholar
  • 20 Anderson G M, Hull E. The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure.  Am Heart J. 1950;  39 697-702
    CrossrefPubMedGoogle Scholar
  • 21 Kierkegaard A, Norgren L, Olsson C-G, Castenfors J, Persson G, Persson S. Incidence of deep vein thrombosis in bedridden non-surgical patients.  Acta Med Scand. 1987;  222 409-414
    PubMedGoogle Scholar
  • 22 Donati M B. Cancer and thrombosis.  Haemostasis. 1994;  24 128-131
    PubMedGoogle Scholar
  • 23 Falanga A, Donati M B. Pathogenesis of thrombosis in patients with malignancy.  Int J Hematol. 2001;  73 137-144
    CrossrefPubMedGoogle Scholar
  • 24 Sutherland D E, Weitz I C, Liebman H A. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment.  Am J Hematol. 2003;  72 43-52
    CrossrefPubMedGoogle Scholar
  • 25 Otten H MMB, Prins M H, Smorenburg S M, Hutten B A. Risk assessment and prophylaxis of venous thromboembolism in non-surgical patients: cancer as a risk factor.  Haemostasis. 2000;  30(Suppl 2) 72-76
    CrossrefPubMedGoogle Scholar
  • 26 Clarke-Pearson D L, Synan I S, Colemen R E, Hinshaw W, Creasman W T. The natural history of postoperative venous thromboemboli in gynaecologic oncology: a prospective study of 382 patients.  Am J Obstet Gynecol. 1984;  148 1051-1054
    PubMedGoogle Scholar
  • 27 Marras L C, Geerts W H, Perry J R. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review.  Cancer. 2000;  89 640-646
    CrossrefPubMedGoogle Scholar
  • 28 Fraisse F, Holzapfel L, Coulaud J-M et al.. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD.  Am J Respir Crit Care Med. 2000;  161 1109-1114
    CrossrefPubMedGoogle Scholar
  • 29 Prescott S M, Richards K L, Tikoff G, Armstrong Jr J D, Shigeoka J W. Venous thromboembolism in decompensated chronic obstructive pulmonary disease: a prospective study.  Am Rev Respir Dis. 1981;  123 32-36
    PubMedGoogle Scholar
  • 30 Miehsler W, Reinisch W, Valic E et al.. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?.  Gut. 2004;  53 542-548
    CrossrefPubMedGoogle Scholar
  • 31 Haas S K. Venous thromboembolic risk and its prevention in hospitalized medical patients.  Semin Thromb Hemost. 2002;  28 577-584
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Motykie G D, Caprini J A, Arcelus J I et al.. Risk factor assessment in the management of patients with suspected deep vein thrombosis.  Int Angiol. 2000;  19 47-51
    PubMedGoogle Scholar
  • 33 Alikhan R, Cohen A T, Combe S et al.. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX Study.  Blood Coagul Fibrinolysis. 2003;  14 341-346
    CrossrefPubMedGoogle Scholar
  • 34 Sandercock P AG, van den Belt A GM, Lindley R I, Slattery J. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials.  J Neurol Neurosurg Psychiatry. 1993;  56 17-25
    PubMedGoogle Scholar
  • 35 Levine M N, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment.  Chest. 2001;  119(Suppl) 108S-121S
    CrossrefPubMedGoogle Scholar
  • 36 Alikhan R, Cohen A T, Combe S et al.. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study.  Arch Intern Med. 2004;  164 963-968
    CrossrefPubMedGoogle Scholar
  • 37 Smeeth L, Cook C, Thomas S et al.. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting.  Lancet. 2006;  367 1075-1080
    CrossrefPubMedGoogle Scholar
  • 38 Samama M-M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients.  Arch Intern Med. 2000;  160 3415-3420
    CrossrefPubMedGoogle Scholar
  • 39 Heit J A, Silverstein M D, Mohr D N et al.. The epidemiology of venous thromboembolism in the community.  Thromb Haemost. 2001;  86 452-463
    PubMedGoogle Scholar
  • 40 Bauer K A. The thrombophilias: well-defined risk factors with uncertain therapeutic implications.  Ann Intern Med. 2001;  135 367-373
    PubMedGoogle Scholar
  • 41 Laffan M, Tuddenham E. Assessing thrombotic risk.  BMJ. 1998;  317 520-523
    PubMedGoogle Scholar
  • 42 Gensini G F, Prisco D, Falciani M, Comeglio M, Colella A. Identification of candidates for prevention of venous thromboembolism.  Semin Thromb Hemost. 1997;  23 55-67
    PubMedGoogle Scholar
  • 43 Abdollahi M, Cushman M, Rosendaal F R. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use.  Thromb Haemost. 2003;  89 493-498
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Goldhaber S Z, Grodstein F, Stampfer M J et al.. A prospective study of risk factors for pulmonary embolism in women.  JAMA. 1997;  277 642-645
    CrossrefPubMedGoogle Scholar
  • 45 Cohen A T, Davidson B L, Gallus A S et al.. Efficacy and safety of fondaparinux for the prevention of VTE in older acute medical patients.  BMJ. 2006;  332 325-329
    CrossrefPubMedGoogle Scholar
  • 46 Leone G, Sica S, Chiusolo P, Teofili L, de Stefano V. Blood cell diseases and thrombosis.  Haematologica. 2001;  86 1236-1244
    PubMedGoogle Scholar
  • 47 Daly E, Vessey M P, Hawkins M M, Carson J L, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy.  Lancet. 1996;  348 977-980
    CrossrefPubMedGoogle Scholar
  • 48 Daly E, Vessey M P, Painter R, Hawkins M M. Case-control study of venous thromboembolism in users of hormone replacement therapy.  Lancet. 1996;  348 1027
    PubMedGoogle Scholar
  • 49 Grady D, Wenger N K, Herrington D et al.. Postmenopausal hormone replacement therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study.  Ann Intern Med. 2000;  132 689-696
    PubMedGoogle Scholar
  • 50 Hulley S, Furberg C, Barrett-Connor E et al.. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS II).  JAMA. 2002;  288 58-66
    CrossrefPubMedGoogle Scholar
  • 51 Bates S M. Treatment and prophylaxis of venous thromboembolism during pregnancy.  Thromb Res. 2002;  108 97-106
    CrossrefPubMedGoogle Scholar
  • 52 Kakkar V V, Corrigan T P, Fossard D P. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: reappraisal of results of international multicentre trial.  Lancet. 1977;  1 567-569
    PubMedGoogle Scholar
  • 53 Carter C J, Kelton J G, Hirsh J et al.. The relationship between haemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits.  Blood. 1982;  59 1239-1245
    PubMedGoogle Scholar
  • 54 Esquivel C O, Bergqvist D, Bjork C G, Nilsson B. Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo.  Thromb Res. 1982;  28 389-399
    CrossrefPubMedGoogle Scholar
  • 55 Cade J F. High risk of the critically ill for venous thromboembolism.  Crit Care Med. 1982;  10 448-450
    CrossrefPubMedGoogle Scholar
  • 56 Cade J F, Andrews J T, Stubbs A E. Comparison of sodium and calcium heparin in prevention of venous thromboembolism.  Aust N Z J Med. 1982;  12 501-504
    PubMedGoogle Scholar
  • 57 Ibarra-Pérez C, Lau-Cortés E, Colmenero-Zubiate S et al.. Prevalence and prevention of deep vein thrombosis of the lower extremities in high-risk pulmonary patients.  Angiology. 1988;  39 505-513
    PubMedGoogle Scholar
  • 58 Gårdlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases.  Lancet. 1996;  347 1357-1361
    CrossrefPubMedGoogle Scholar
  • 59 Mismetti P, Laporte-Simitsidis S, Tardy B et al.. Prevention of venous thromboembolism in internal medicine with unfractionated heparin or low-molecular-weight heparins: a meta-analysis of randomised clinical trials.  Thromb Haemost. 2000;  83 14-19
    PubMedGoogle Scholar
  • 60 Mahe I, Bergmann J F, d'Azemar P, Vaissie J J, Caulin C. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomized double-blind study.  Eur J Clin Pharmacol. 2005;  61 347-351
    CrossrefPubMedGoogle Scholar
  • 61 Dentali F, Douketis J D, Gianni M, Lim W, Crowther M A. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients.  Ann Intern Med. 2007;  146 278-288
    CrossrefPubMedGoogle Scholar
  • 62 Lechler E, Schramm W, Flosbach C W. for THE PRIME Study Group . The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin).  Haemostasis. 1996;  26(Suppl 2) 49-56
    PubMedGoogle Scholar
  • 63 Kleber F-X, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach C W. for THE PRINCE Study Group . A randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.  Am Heart J. 2003;  145 614-621
    CrossrefPubMedGoogle Scholar
  • 64 Hillbom M, Erilä T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Enoxaparin vs heparin for prevention of deep vein thrombosis in acute ischaemic stroke: a randomized, double-blind study.  Acta Neurol Scand. 2002;  106 84-92
    CrossrefPubMedGoogle Scholar
  • 65 Antiplatelet Trialists' Collaboration . Collaborative overview of randomised trials of antiplatelet therapy-3: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients.  BMJ. 1994;  308 235-246
    Google Scholar
  • 66 Mazzone C, Chiodo F G, Sandercock P, Miccio M, Salvi R. Physical methods for preventing deep vein thrombosis in stroke.  Cochrane Database Syst Rev. 2004;  (4) CD001922
    PubMedGoogle Scholar

Dr. Alexander T Cohen

Vascular Medicine, Department of Vascular Surgery, King's College Hospital

Bessemer Rd., London SE5 9RS, United Kingdom

Email: alexander.cohen@kcl.ac.uk

      >